

Smooth Muscle Motility: Comparing the Effect of a Synthetic Anti-Diarrhoeal Drug with a Probiotic on an Isolated Rabbit Intestine

Rabiu A.M, Idah O.V, Yilgwan G, Wale H.R, Dimka L.Y, Musa F.T, Galam N.Z, Ayaka L, Mosugu O.O, Shugaba A.I, Odeh S.O

Abstract— Background: Diarrhoea exerts an enormous toll in terms of mortality, morbidity, social inconvenience, loss of work productivity, and consumption of medical resources. Acute infectious diarrhea remains one of the most common causes of mortality in developing countries, particularly among children, accounting for 2-3 million deaths per year.

Aim: To compare the contractile effect of a synthetic anti-spasmodic and a probiotic drug on an isolated rabbit intestine.

Method: A healthy rabbit weighing 300g was humanely sacrificed and a length of a small intestine (ileum) was isolated and submerged in a tissue bath. The test solutions (*Saccharomyces boulardii*, Synthetic anti-spasmodic) were then applied in graded doses and the final bath concentration calculated.

Results: The experimental data was analyzed using T-test of Independent variable and the output clearly revealed that there was no significant difference ($p = 0.73$) in the Amplitude between the two drugs. But there was a significant difference observed in the frequency between the two drugs ($p = 0.002$).

Conclusion: *S. boulardii* is a well tolerated probiotic with little or no side effects that has some effect on intestinal motility.

Index Terms— Diarrhoea, Synthetic anti-spasmodic (Loperamide), *Saccharomyces boulardii*, Rabbit, Ileum

I. INTRODUCTION

Diarrhoea is defined as passage of abnormally liquid or unformed stools at an increased frequency. Diarrhoea exerts an enormous toll in terms of mortality, morbidity, social inconvenience, loss of work productivity, and consumption

Rabiu A.M, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria,

Idah O.V, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria,

Yilgwan G, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Wale H.R, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Dimka L.Y, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Musa F.T, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Galam N.Z, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Ayaka L, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria

Mosugu O.O, Department of Human Anatomy, Faculty of Medical Sciences, University of Jos, Jos, Nigeria.

Shugaba A.I, Department of Human Anatomy, Faculty of Medical Sciences, University of Jos, Jos, Nigeria.

Odeh S.O, Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Jos, Nigeria.

of medical resources. Worldwide, more than one billion individuals suffer one or more episodes of acute diarrhea each year. Among the 100million persons affected annually by acute diarrhea in the United States, nearly half must restrict activities, 10% consult Physicians, approximately 250,000 require hospitalization, and approximately 5000 die (primarily the elderly). The annual economic burden to society may exceed \$20 billion. Acute infectious diarrhea remains one of the most common causes of mortality in developing countries, particularly among children, accounting for 2-3 million deaths per year (Harrison's Principle of internal medicine, 17th edition, 2008).

Diarrhoea results from an imbalance between secretion and re-absorption of fluid and electrolytes; it has numerous causes, including infections with enteric organisms, inflammatory bowel disease and nutrient mal-absorption due to disease (Bennett and Brown 2003). Motility patterns in the bowel is an important factor in diarrhoea may be caused by loss of the normal segmenting contractions that delay passage of contents, so that an occasional peristaltic wave has a greater propulsive effect. Segmental contractions of the smooth muscle in the bowel mix the intestinal contents. Patients with diarrhoea commonly have less spontaneous segmenting activity in the sigmoid colon than do people with normal bowel habit and patients with constipation have more. Anti-motility drugs reduce diarrhoea by increasing segmentation and inhibiting peristalsis, e.g., Loperamide (Bennett and Brown 2003).

Loperamide is a derivative of meperidine. It exerts its anti-motility action through binding to opioid receptors in the intestine as well as inhibiting calcium channels and calmodulin in intestinal smooth muscle. In addition, it inhibits fluid secretion by the colonic epithelial cells. Because of its limited oral bioavailability and poor penetration across the blood-brain barrier, loperamide is a good anti-diarrheal agent with minimal side effects, especially central nervous system-related effects (Lingtak-Neander 2008).

Saccharomyces boulardii is a tropical strain of yeast first isolated from lychee and mangosteen fruits in 1923 by French scientist Henri Boulard. It is related to, but distinct from, *saccharomyces cerevisiae* in several taxonomic, metabolic and genetic properties (Malgoire et al., 2005). *S. boulardii* is sometimes used as a probiotic with the purpose of introducing beneficial active cultures into the large and small intestine, as well as conferring protection against pathogenic microorganisms in the Host (Rajkowska et al., 2012).

Smooth Muscle Motility: Comparing the Effect of a Synthetic Anti-Diarrhoeal Drug with a Probiotic on an Isolated Rabbit Intestine

However, in immuno-compromised individuals, *S. boulardii* has been associated with (fungemia) or localized infection, which may be fatal (Santino et al., 2014).

While the mechanisms by which probiotics exert their benefit are not fully understood, it has been suggested that they improve host barrier function, produce competitive inhibition of pathogenic bacteria, and bolster immune function. *S. boulardii* secretes enzymatic proteins, including a protease that degrades clostridium difficile toxins and a phosphatase that inactivates endotoxins such as the lipopolysaccharide produced by *E. coli*. It also strengthens tight junctions between enterocytes (reducing secretory IgA) (Marcia 2009).

II. MATERIALS/METHOD

The animal (Healthy Rabbit, male, 300g) was purchased and housed at the University of Jos animal house under humane condition in line with the Helsinki declaration, ethical clearance was sought and gotten from the animal house ethical committee. The rabbit was humanely sacrificed and a length of a small intestine (ileum) was isolated, washed and placed into the petri dish containing tyrodesolution (370c), with air bubbled through the aerator (to keep the tissue alive). The isolated segment of the intestine was tied with a thread at each end and suspended into the tissue bath and the other end tied to the writing lever, the tissue was allowed to acclimatize within the new environment for 15 minutes. A spontaneous rhythmic contraction was noted, the kymograph speed was set at 0.25mm/sec, and the normal spontaneous contraction was recorded for 2 minutes. The test solutions (*Saccharomyces boulardii*, Loperamide hydrochloride) were then added. The tissue was washed 2-3 times until it recovered from the effect of the last test solution and a normal tracing is recorded before the next test solution was applied into the organ bath. A sufficient time of about 3-4 minutes was allowed for each test solution to penetrate the tissue; the test solutions were prepared in graded concentrations using x 10 dilution and the final bath concentration was calculated using the formula $C_1 = \frac{C_2 \times V_2}{V_1}$

Where: C1 = stock (concentration of drugs), C2 = required final bath concentration of drugs, V1 = volume of drugs used, V2 = volume of tissue bath






Saccharomyces boulardii; (0.0005, 0.005, 0.05 and 0.5) mg/ml

Loperamide hydrochloride; (0.002, 0.02, 0.2 and 2) mg/ml.

III. RESULTS

The experimental data was analyzed using T-test of Independent variable and the output clearly revealed no significant difference ($p = 0.73$) in the Amplitude between the two drugs. However a significant difference was clearly observed in the frequency between the two drugs ($p = 0.002$).

Plate: below is the tracing from the contraction of the rabbit intestine (ileum) following the application of the test solution and different concentrations;



A. Amplitude

There was no significant mean difference in amplitude between Probiotic and the synthetic anti-spasmodic drug.

Table 1: Shows the Mean amplitude Difference between Probiotic and Synthetic anti-spasmodic drug .

Drug	N	Mean	Sig. (2 tailed)
Probiotic	4	20.4	0.73
Synthetic drug	4	17.8	

P > 0.05

The result in Table 1 shows that there is no statistically significant mean difference in amplitude between Probiotic and the Synthetic anti-spasmodic drug ($t_6 = 0.362$, $p > 0.05$). However, Despite the no statistically significance in the effectiveness of the two drugs, the result indicate that the Probiotic have a higher mean amplitude effectiveness of 20.4 than the synthetic anti-spasmodic drug which mean amplitude is 17.8.

B. Frequency

There is a significant mean difference in frequency between Probiotic and the synthetic anti-spasmodic drug.

Table 2: Shows the Mean frequency Difference between Probiotic and Synthetic anti-spasmodic drug.

Drug	N	Mean	Sig. (2 tailed)
Probiotic	4	9	0.002
Synthetic drug	4	4.5	

P < 0.05

The result in Table 2 shows a statistically significant mean difference in frequency between Probiotic and the Synthetic anti-spasmodic drug. ($t_6 = 5.362$, $p < 0.05$). In other words, the probiotic drug has a statistically significant higher average frequency of 9 than the Synthetic anti-spasmodic drug with a mean frequency of 4.5.




Figure 1b: Showing frequency of Probiotic at final bath concentration of the test solution




Figure 2a: Showing Amplitude of Imodium at final bath concentration of the test solution




Figure 1a: Showing Amplitude of Probiotic at final bath concentration of the test solution




Figure 2b: Showing frequency of Imodium at final bath concentration of the test solution

IV. DISCUSSION

Our study compares the action of a synthetic

Opiodanti-spasmodic and a probiotic (*Saccharomyces boulardii*) on the motility of an isolated segment of a rabbit intestine. The result revealed no significant difference ($p < 0.73$) in the amplitude between the two drugs. The probiotic reduces the amplitude of the rabbits smooth intestinal muscle (figure 1) at very low concentration (0.005mg/ml) and at high concentration (0.5mg/ml), while the synthetic anti-spasmodic drug does same at a concentration of 0.02mg/ml. A significant difference ($P < 0.002$) was clearly observed in the frequency between the two drugs as stated. In a study by Micklefield on *Saccharomyces boulardii* in the treatment and prevention of antibiotic-associated diarrhea (AAD), in 14 out of 17 studies including 4,627 patients the administration of *S. boulardii* achieved a protective effect between 43.7% and 87.3% (Micklefield; 2014). The use of anti-motility drugs in diarrhoea in children (less than 4 years) is discouraged or in patients with active anti-inflammatory bowel disease, for there is danger of causing paralytic ileus and, in babies, respiratory depression (Bennett and Brown; 2003). In another study by Dinleyici et al., on *Saccharomyces boulardii* CNCM 1-745 in different clinical conditions *S. boulardii* is shown to be one of the best-studied probiotics in acute gastroenteritis (AGE) and is shown to be safe and to reduce the duration of diarrhoea and hospitalization by about 1 day (Dinleyici et al., 2014). There is a dearth of research data on the use of *S. boulardii* on smooth muscle motility. However, our work showed that it has some effect at very low concentrations only, while the synthetic anti-spasmodic drug has a maximal anti-motility effect at all concentration used.

In conclusion, diarrhoeal disease contributes not only to morbidity and mortality in the world but also to school and work absenteeism with negative impact on productivity. *S. boulardii* is a well tolerated probiotic anti-diarrhoeal drug with little or no side effects that has some effect on intestinal motility. Thus, an effective and well tolerated anti-diarrhoeal drug will reduce morbidity and mortality.

REFERENCES

[1] Bennett PN, Brown MJ. Anti-diarrheal drugs. *Clinical Pharmacology* 2003; 32: 643-644

[2] Castaneda C, Garcia E, Santa Cruz M, Fernandez M, Monterrey P (1995). Effects of *saccharomyces boulardii* in children with chronic diarrhea, especially cases due to giardiasis. *Rev Mex Pueric Pediatr* 2: 12-6

[3] Centina-Sauri G, Sierra Basto G (1994). Therapeutic evaluation of *Saccharomyces boulardii* in children with acute diarrhea. *Ann Pediatr* 41; 397-400.

[4] Dinleyici EC, Kara A, Ozen M, Vandenplas Y. *Saccharomyces boulardii* CNCM 1-745 in different clinical conditions. *Expert Opin Biol Ther*. 2014 Jul 4; 1-17

[5] Gaon D, Garcia H, Winter L (2003). Effects of *Lactobacillus* Strains and *saccharomyces boulardii* on persistent diarrhea in children. *Medicina (B Aires)* 63: 293-298

[6] Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000). *Saccharomyces boulardii* in maintenance treatment of Crohn's disease: *Dig. Dis. Sci.* 45(7): 1462-4

[7] Harrison's Principle of internal medicine, 17th edition, 2008, Chapter 40. diarrhoea and constipation.

[8] Hennequin C, Kauffmann-Lacroix C, Jobert A, Viard JP, Ricour C, Jacquemin JL et al (2000). Possible role of catheters in *saccharomyces boulardii* fungaemia. *Eur J Clin Microbiol Infect Dis* 19: 16-20

[9] Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic *saccharomyces boulardii* for the prevention and therapy of gastrointestinal disorders. *Ther Adv Gastroenterol* (2012) 5(2) 111-125

[10] Kollaritch H, Kemsner P, Wiedermann G, Scheiner O (1989). Prevention of traveller's diarrhea, comparison of non-antibiotic preparations. *Travel Med Int*: 9-17

[11] Malgoire J.Y, bertont S, Renard F, Bastide Jm, Mallie M (2005). Typing of *sacchrimycesceresiae* clinical strains by using micro satellite polymorphism". *J.ccin microbial* 43(3): 1133-7

[12] Marcia LB. *Saccharomyces boulardii* as a probiotic for children. *Pediatr Pharm*. 2009; 15(7).

[13] Maupas J, Champemont P, Delforge M (1983). Treatment of irritable bowel syndrome with *saccharomyces boulardii*: a double blind, placebo controlled study. *Medicine Chiruvgie Digestives* 12(1) 77-9

[14] McFarland L, Bernasconi P (1993). *Saccharomyces boulardii*: a review of an innovative biotherapeutic agent. *MicrobEcol Health Dis* 6(4): 157-71.

[15] McFarland L, Surawicz C, Greenberg R (1994). A randomized placebo-controlled trial of *saccharomyces boulardii* in combination with standard antibiotics for *clostridium difficile* disease. *J Am Med Assoc* 271(24): 1913-8.

[16] McFarland LV, Surawicz CM, Greenberg RN et al (1995). Prevention of beta-lactam-associated diarrhea by *saccharomyces boulardii* compared with placebo. *Am J Gastroenterol*. 90(3): 439-48

[17] Micklefield G. *Saccharomyces boulardii* in the treatment and prevention of antibiotic-associated diarrhea. *Mmw Fortschr Med*. 2014. Apr 17;156 supp (1): 18-22

[18] Rajkowska, katarzyna; et al (April 2012). "Probiotic activity of *saccharomyces cereisiae* Var. *boulardii* against human pathogens. *Food Technology and Biotechnology* 50: 230-236.

[19] Saint-marc T, Blehant H, Musial C, Touraine J (1995). AIDS related diarrhea: a double-blind trial of *saccharomyces boulardii*. *Sem Hosp Paris* 71: 735-41

[20] Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, Magrini L, Disomma S, Teggi A. *Saccharomyces Cerevisiae* fungaemia, a possible consequence of the treatment of *clostridium difficile* colitis with a probioticum. *Int J Immunopathol Pharmacol* 2014, 27(1): 143-6.

[21] Whelan K, Myers CE (2010). Safety of probiotics in patients receiving nutritional support: a systemic review of case reports, randomized controlled trials, and nonrandomized trials. *Am J Clin Nutr* 91: 687-703.